Appointment of Maziar Mike Doustdar as Novo Nordisk's President and CEO

Novo Nordisk announced the appointment of Maziar Mike Doustdar as its new president and chief executive officer, effective 7 August 2025. Doustdar, currently the executive vice president of International Operations, will succeed Lars Fruergaard Jørgensen. Under Doustdar's leadership, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The company also announced other executive-level changes, including the merger of Research & Early Development and Development into a consolidated R&D unit under Martin Holst Lange, who will be appointed chief scientific officer. Marcus Schindler, the current executive vice president of Research & Early Development and CSO, will retire. Emil Kongshøj Larsen will succeed Doustdar as executive vice president of International Operations. These changes aim to drive growth and innovation in the diabetes and obesity areas.